SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF A FOREIGN ISSUER
PURSUANT TO RULE13A-16 OR15D-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For November 19, 2019
Commission File Number1-38455
MorphoSys AG
Semmelweisstrasse 7
82152 Planegg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.
Form20-F ☒ Form40-F ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule12g3-2(b):
EXHIBIT 99.1 TO THIS REPORT ON FORM6-K IS INCORPORATED BY REFERENCE IN THE REGISTRATION STATEMENT ON FORMS-8 (FILE NO.333-226422) OF MORPHOSYS AG AND IN THE OUTSTANDING PROSPECTUS CONTAINED IN SUCH REGISTRATION STATEMENT.
Exhibits
99.1 | Ad hoc: MorphoSys’ tafasitamabB-MIND DLBCL study successfully passed futility analysis | |
99.2 | MorphoSys’ tafasitamabB-MIND DLBCL study successfully passed futility analysis |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MORPHOSYS AG (Registrant) | ||||||
Date: November 19, 2019 | By: | /s/ Dr. Sarah Fakih | ||||
Name: | Dr. Sarah Fakih | |||||
Title: | Vice President | Head of Corporate Communications & IR | |||||
By: | /s/ Dr: Julia Neugebauer | |||||
Name: | Dr. Julia Neugebauer | |||||
Title: | Director Corporate Communications and Investor Relations |